Double Bond Pharmaceutical Worldwide AB (publ) (“DBP”) notes the announcement launched earlier yesterday by Hemcheck Sweden AB  (“Hemcheck”) and is happy to announce that its 20% owned investee firm Bio Vitos has right now entered into an settlement with Hemcheck, an organization listed on the Nasdaq Stockholm (the “Settlement”).  As a part of the Settlement Hemcheck will create a brand new subsidiary (“NewCo”) and switch all present enterprise and property of Hemcheck to this new subsidiary. Underneath the phrases of the Settlement, Bio Vitos has agreed to offer the NewCo with  SEK1.23 million in money, plus any relevant VAT, on signing of the Settlement,  inside 14 days after the distribution of the shares in NewCo to Hemcheck’s shareholders.


Bio Vitos will then pay an extra SEK4 million in money, plus any relevant VAT, to Hemcheck, inside thirty days following the distribution of shares in NewCo to Hemcheck Sweden AB shareholders. 


As well as Bio Vitos has agreed to offer Hemcheck with its IP rights (patents or patent functions) in respect of  an lively substance Iron Succinate (Succifer and utilized in a marketed product Inofer). In change, Bio Vitos will obtain 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck’s share capital.


DBP’s holding in Bio Vitos will stay unchanged.


The Board  of DBP is knowledgeable by Bio Vitos that below the foundations of the Nasdaq Stockholm that is deemed to represent a reverse takeover for Hemcheck. It’s anticipated that topic to all required shareholder and regulatory approvals, that Hemcheck will stay listed on the Nasdaq Stockholm.


The complete textual content of the announcement launched by Hemcheck yesterday:


Extra about DBP’s place in Bio Vitos:


This disclosure accommodates info that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The data was submitted for publication, via the company of the contact individual, on 08-02-2023 07:48 CET.

Details about Double Bond Pharmaceutical AB:

DBP is a pharmaceutical firm with the first deal with improvement of therapies in opposition to most cancers based mostly on the corporate’s personal developed drug supply know-how BeloGal®. The corporate was granted Orphan Drug Designation standing by European Medicines Company (EMA) in June 2015 for its first product, SA-033, for therapy of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for therapy of mind tumours, in October 2015, and was granted Orphan Drug Designation standing by EMA for in July 2016 for this formulation of temozolomide for the therapy of glioma. The formulation is now being additional developed for registration in EU and globally and has a working title SI-053 in DBP pipeline.


Full Firm Identify:   Double Bond Pharmaceutical Worldwide AB (publ)

Company id:       556991-6082

Inventory brief title:       DBP B

Share ISIN code:          SE0007185525


For more information, contact

Igor Lokot, CEO


E-mail: [email protected]


Observe us on LinkedIn and Twitter!


(c) 2023 Cision. All rights reserved., supply Press Releases – English